Liver Cancer/HCC
Liver Cancer/HCC
EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 20 April 2017 00:00
- Written by Liz Highleyman
The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.
CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
- Details
- Category: HCV Disease Progression
- Published on Friday, 17 February 2017 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Sunday, 20 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/20/16
AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
Nivolumab (Opdivo), an antibody that blocks the PD-1 receptor and restores T-cell anti-tumor activity, appeared safe and was associated with disease control and stabilization in a Phase 1/2 study of patients with hepatocellular carcinoma, according to late-breaking results from the CheckMate 040 study presented at the AASLD Liver Meeting last month in Boston.
AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 13 November 2016 00:00
- Written by Keith Alcorn
People who are cured of hepatitis C after a course of direct-acting antiviral treatment do not have a higher risk of developing hepatocellular carcinoma (HCC) -- and probably have a reduced risk -- according to studies from Italy and Canada presented at American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
More Articles...
- EASL 2016: People Treated for Hepatitis C Have Unexpectedly High Rate of Liver Cancer Recurrence
- Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
- Coverage of the 2015 AASLD Liver Meeting
- AASLD 2015: People with Cirrhosis Cured of Hepatitis C Still Have Elevated Liver Cancer Risk
Web Design and Development by